TP53 and cancer: Alternatively, actual the rate of cancer onset during their lifetime may be lower than assumed, although it is assumed that almost all individuals with TP53 pathogenic variant are going to develop cancer at least once in their lifetime; thus, the clinical presentation of LFS is still not elucidated.